RECRUITING

Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this trial is to test the efficacy of a collaborative care intervention to address opioid- and/or stimulant-involved polysubstance use in adult primary care patients with moderate to severe substance use disorders (SUD). The primary aims are to reduce days of opioid use (illicit or nonmedical opioid use), days of illicit stimulant use (cocaine, methamphetamine), and days of heavy alcohol use.

Official Title

NIDA CTN Protocol 0139: Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care)

Quick Facts

Study Start:2024-10-24
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06116266

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Licensed medical professional (MD, DO, NP, PA) who is able to prescribe controlled substances (Schedule III), or medical trainee meeting the requirements below.
  2. * Serves as a primary care provider to adult patients (18 years of age and over) of the study clinic(s) during direct patient care sessions.
  3. * Willing to be randomized to either of the study conditions. a. Medical trainees (physicians who are residents or fellows), are eligible if they have at least one continuity clinic session per week on average in the study clinic. Trainees must have plans to be working in a study clinic for approximately 8 months or longer. They must be able to provide prescriptions for controlled substances (Schedule III) either directly or through their preceptor(s).
  1. * Definite plan to resign from the clinic in the next eight months, per PCP self-report. Residents and fellows will need at least eight months before training completion to enroll.

Contacts and Locations

Study Contact

Rebecca Stone, MPH
CONTACT
Rebecca.stone@nyulangone.org
Noa Appleton, MPH
CONTACT
Noa.Appleton@nyulangone.org

Principal Investigator

Jennifer McNeely, MD
PRINCIPAL_INVESTIGATOR
NYU Langone Health

Study Locations (Sites)

Harbor-UCLA Medical Center
Torrance, California, 90502
United States
NYU Langone Health
New York, New York, 10016
United States
The Institute for Family Health
New York, New York, 10025
United States
Winding Waters Medical Clinic
Enterprise, Oregon, 97828
United States
Union Community Care
Lancaster, Pennsylvania, 17603
United States
Harris Health
Houston, Texas, 77030
United States
Sea Mar Community Health Centers
Bellingham, Washington, 98226
United States
Wisconsin Research & Education Network
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Jennifer McNeely, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-24
Study Completion Date2026-12

Study Record Updates

Study Start Date2024-10-24
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Substance Use